Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01023308 | Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma(PANORAMA-1) | completed | Phase 3 | 767 | Novartis PharmaceuticalsINDUSTRY | 34 | Mar 17, 2020 | clinicaltrials |
| NCT01569295 | Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )(Tugela) | completed | Phase 3 | 416 | Gilead SciencesINDUSTRY |
| 18 |
| Mar 10, 2020 |
| clinicaltrials |
| NCT00707083 | Two Combination Chemotherapy Regimens in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 3 | 2,231 | Prince of Wales Hospital, Shatin, Hong KongOTHER | 1 | Mar 5, 2020 | clinicaltrials |
| NCT02870777 | MRD-directed Therapy for Low-risk and Intermediate-risk AML. | completed | Phase 2 / Phase 3 | 743 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT01611090 | A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 3 | 578 | Janssen Research & Development, LLCINDUSTRY | 21 | Mar 3, 2020 | clinicaltrials |
| NCT02671708 | IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT | completed | Phase 2 / Phase 3 | 153 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Mar 3, 2020 | clinicaltrials |
| NCT02801578 | A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 / Phase 3 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 27, 2020 | clinicaltrials |
| NCT00952588 | Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients(SPARK-AML1) | completed | Phase 2 / Phase 3 | 74 | AstraZenecaINDUSTRY | 9 | Feb 24, 2020 | clinicaltrials |
| NCT00262782 | Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia | completed | Phase 3 | 877 | German CLL Study GroupOTHER | 2 | Feb 20, 2020 | clinicaltrials |
| NCT00088530 | BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) | completed | Phase 3 | 140 | CTI BioPharmaINDUSTRY | 20 | Feb 5, 2020 | clinicaltrials |
| NCT02162771 | To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan(rituximab) | completed | Phase 3 | 140 | CelltrionINDUSTRY | 0 | Jan 29, 2020 | clinicaltrials |
| NCT02696408 | Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation(STOP MUCITES) | completed | Phase 3 | 234 | Institut de Cancérologie de la LoireOTHER | 1 | Jan 29, 2020 | clinicaltrials |
| NCT00887068 | Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) | completed | Phase 3 | 187 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT01059630 | A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN) | completed | Phase 3 | 413 | Genentech, Inc.INDUSTRY | 14 | Jan 13, 2020 | clinicaltrials |
| NCT01118234 | Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) | completed | Phase 3 | 256 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 3 | Jan 9, 2020 | clinicaltrials |
| NCT01146834 | Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma | completed | Phase 3 | 47 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT01578707 | A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(RESONATE™) | completed | Phase 3 | 391 | Pharmacyclics LLC.INDUSTRY | 10 | Dec 18, 2019 | clinicaltrials |
| NCT00814073 | Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis(AB06006) | completed | Phase 3 | 135 | AB ScienceINDUSTRY | 2 | Dec 3, 2019 | clinicaltrials |
| NCT01197560 | Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | completed | Phase 2 / Phase 3 | 111 | CelgeneINDUSTRY | 9 | Nov 25, 2019 | clinicaltrials |
| NCT00622336 | A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma | completed | Phase 3 | 330 | CelgeneINDUSTRY | 2 | Nov 20, 2019 | clinicaltrials |
| NCT00689936 | Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma(FIRST) | completed | Phase 3 | 1,623 | CelgeneINDUSTRY | 19 | Nov 20, 2019 | clinicaltrials |
| NCT00928486 | A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma | completed | Phase 3 | 25 | CelgeneINDUSTRY | 1 | Nov 20, 2019 | clinicaltrials |
| NCT01324947 | Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma | completed | Phase 3 | 74 | CelgeneINDUSTRY | 15 | Nov 19, 2019 | clinicaltrials |
| NCT00452569 | Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma(OPTIMUM) | completed | Phase 3 | 499 | CelgeneINDUSTRY | 15 | Nov 18, 2019 | clinicaltrials |
| NCT02811978 | Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma | completed | Phase 3 | 81 | Janssen Research & Development, LLCINDUSTRY | 1 | Nov 8, 2019 | clinicaltrials |
| NCT01905943 | A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia | completed | Phase 3 | 979 | Hoffmann-La RocheINDUSTRY | 31 | Oct 28, 2019 | clinicaltrials |
| NCT00657488 | Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma | completed | Phase 2 / Phase 3 | 400 | CelgeneINDUSTRY | 2 | Oct 18, 2019 | clinicaltrials |
| NCT03349333 | A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL | completed | Phase 3 | 85 | Mundipharma (China) Pharmaceutical Co. LtdINDUSTRY | 1 | Oct 1, 2019 | clinicaltrials |
| NCT02268045 | Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma | completed | Phase 3 | 272 | mAbxience Research S.L.INDUSTRY | 12 | Sep 26, 2019 | clinicaltrials |
| NCT01305200 | Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant | completed | Phase 3 | 226 | Children's Oncology GroupNETWORK | 3 | Sep 17, 2019 | clinicaltrials |
| NCT00260832 | Trial of Decitabine in Patients With Acute Myeloid Leukemia | completed | Phase 3 | 485 | Eisai Inc.INDUSTRY | 15 | Sep 11, 2019 | clinicaltrials |
| NCT00137995 | R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma | completed | Phase 3 | 481 | Lymphoma Study AssociationOTHER | 10 | Aug 28, 2019 | clinicaltrials |
| NCT01818752 | Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma(CLARION) | completed | Phase 3 | 955 | AmgenINDUSTRY | 30 | Aug 26, 2019 | clinicaltrials |
| NCT02474290 | Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML | completed | Phase 2 / Phase 3 | 202 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT02272777 | A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase | completed | Phase 3 | 225 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 19, 2019 | clinicaltrials |
| NCT00382109 | Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission | completed | Phase 3 | 146 | Children's Oncology GroupNETWORK | 3 | Aug 7, 2019 | clinicaltrials |
| NCT00004228 | Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma | completed | Phase 3 | 393 | Children's Oncology GroupNETWORK | 5 | Aug 6, 2019 | clinicaltrials |
| NCT02292446 | Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. | completed | Phase 3 | 161 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 18, 2019 | clinicaltrials |
| NCT01178281 | Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence(RESUME) | completed | Phase 3 | 267 | CelgeneINDUSTRY | 16 | Jul 17, 2019 | clinicaltrials |
| NCT00910910 | Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)(ORIGIN) | completed | Phase 3 | 450 | CelgeneINDUSTRY | 27 | Jul 9, 2019 | clinicaltrials |
| NCT00210353 | Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma | completed | Phase 3 | 454 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 6 | Jun 6, 2019 | clinicaltrials |
| NCT02042690 | Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients | completed | Phase 3 | 131 | Peking UniversityOTHER | 1 | May 29, 2019 | clinicaltrials |
| NCT00262795 | Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia | completed | Phase 3 | 206 | German CLL Study GroupOTHER | 2 | May 23, 2019 | clinicaltrials |
| NCT00275054 | Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia | completed | Phase 3 | 825 | German CLL Study GroupOTHER | 3 | May 23, 2019 | clinicaltrials |
| NCT00276848 | Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia | completed | Phase 3 | 375 | German CLL Study GroupOTHER | 2 | May 23, 2019 | clinicaltrials |
| NCT00003280 | Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma | completed | Phase 3 | 240 | Swiss Cancer InstituteOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT00227695 | Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma | completed | Phase 3 | 270 | Swiss Cancer InstituteOTHER | 7 | May 15, 2019 | clinicaltrials |
| NCT01539512 | A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) | completed | Phase 3 | 220 | Gilead SciencesINDUSTRY | 5 | May 14, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Mar 17, 2020source: clinicaltrials